Europas førende søgning efter kliniske forsøg

SC0062

Clinical trials are investigating N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N’-(2-METHOXYETHYL)SULFURIC DIAMIDE in people with chronic kidney disease and type 1 diabetes. The study looks at whether it can help reduce kidney damage, especially albumin in the urine, and compares it with a combination treatment. The trial is in an early phase and was planned for adults with higher urinary albumin levels.

Table of contents

Trial overview

The available trial studied N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N’-(2-METHOXYETHYL)SULFURIC DIAMIDE in people with chronic kidney disease and type 1 diabetes.[1] The study aimed to examine whether the treatment could help prevent kidney injury, especially by lowering albumin in the urine.[1]

Who was studied

The trial was planned for adults with type 1 diabetes and chronic kidney disease.[1] It also focused on people with elevated urinary albumin excretion, which means they had more albumin in the urine than expected.[1]

What the study measured

The main result measure was the change from baseline in urine albumin-creatinine ratio (UACR).[1] This is a urine test used to track how much albumin is leaking into the urine over time.[1] The study compared SC0062 alone with a combination of dapagliflozin and SC0062.[1]

Trial phase and status

This was a Phase 2 study, which means it was an early study looking for signs that the treatment might help and continuing to collect research data.[1] The study status was Withdrawn, meaning it was stopped before participants were enrolled.[1] The planned enrollment was 36 participants.[1]

Treatments being compared

The trial compared two study approaches: SC0062 alone and dapagliflozin plus SC0062.[1] The purpose was to see whether adding dapagliflozin changed albuminuria results compared with SC0062 alone.[1]

Patient-friendly terms

Albuminuria means too much albumin, a protein, is passing into the urine.[1] Renal injury means kidney damage.[1] Interventional study means researchers give a treatment and measure what happens.[1]

Trial ID Phase Condition studied Status Enrollment
NCT06072326 Phase 2 Chronic Kidney Disease, Type 1 Diabetes Withdrawn 36

FAQ

  • What is being studied in these clinical trials? The trial is studying N-[5-(2H-1,3-BENZODIOXOL-5-YL)-6-{2-[(5-BROMOPYRIMIDIN-2-YL)OXY]ETHOXY}PYRIMIDIN-4-YL]-N'-(2-METHOXYETHYL)SULFURIC DIAMIDE, alone and together with dapagliflozin. The main question is whether these treatments can lower albumin in the urine, which is a sign of kidney injury.
  • Who was planned to join the study? The study was planned for adults with type 1 diabetes and chronic kidney disease. People also needed to have increased urinary albumin excretion, meaning more albumin in the urine than normal.
  • What phase was the trial in? This was a Phase 2 trial. Phase 2 studies usually look at early signs of benefit and continue to collect safety and effectiveness information.
  • What condition was the trial focused on? The trial focused on chronic kidney disease in people with type 1 diabetes. It was designed to study prevention of renal injury, which means kidney damage.
  • What was the main outcome being measured? The main outcome was the change from baseline in urine albumin-creatinine ratio, also called UACR. This test helps show how much albumin is leaking into the urine over time.

Igangværende kliniske forsøg for SC0062

  • Undersøgelse af dapagliflozin og SC0062 til behandling af kronisk nyresygdom hos voksne patienter med type 1-diabetes

    Rekrutterer endnu ikke

    1 1 1
    Undersøgte sygdomme:
    Undersøgte lægemidler:
    Danmark Finland Holland

Ordliste

  • Chronic kidney disease: A long-lasting condition in which the kidneys do not work as well as they should.
  • Type 1 diabetes: A condition where the body does not make insulin, so blood sugar must be managed with treatment.
  • Albuminuria: Having too much albumin, a protein, in the urine. This can be a sign of kidney damage.
  • Urine albumin-creatinine ratio (UACR): A urine test that compares albumin to creatinine to estimate how much protein is leaking into the urine.
  • Baseline: The starting point before treatment begins, used for comparison later.
  • Phase 2: An early stage of clinical research that checks whether a treatment shows promise and continues to monitor safety.
  • Interventional study: A study where researchers give a treatment and then measure what happens.
  • Randomized evaluation: A study design where participants are assigned to different treatment groups by chance.
  • Renal injury: Damage to the kidneys.
  • Withdrawn: The study was stopped before it began enrolling participants.